UK bioscience incubator, BioCity Group, has been listed in the Financial Times' FT 1000 report, a list of Europe's 1,000 fastest-growing companies.
This was the first time that the FT sought to identify the 1,000 European companies with the strongest growth, focussing on 2012–2015.
BioCity and one of the companies based at BioCity, Sygnature Discovery, both made the top 200 in the UK.
BioCity specialises in the creation and development of life science businesses. It provides homes and access to high-end equipment, shared services, training, business support and access to investment for new and growing bioscience businesses.
Paul Oliver, Chief Financial Officer at BioCity Group, said:
“We have an incredible 91% 'survival rate' of companies at BioCity in Nottingham and that is something we are replicating across our sites.”
Paul Clewlow, Senior VP of Business Development at Sygnature Discovery, said:
“To be included in the FT 1000 demonstrates increasing demand from pharmaceutical and biotech clients for our integrated drug discovery expertise. There are only five other pharmaceutical companies in this list.”
BioCity will now be featured in a special report in a weekday edition of the FT newspaper.
